Oxford Biomedica PLC Director Dealings (1472R)
September 19 2017 - 2:58AM
UK Regulatory
TIDMOXB
RNS Number : 1472R
Oxford Biomedica PLC
19 September 2017
Director Dealings / Market Share Sale and Purchase
Oxford, UK - 19 September 2017: Oxford BioMedica plc ("Oxford
BioMedica" or "the Company") (LSE: OXB), a leading gene and cell
therapy group, was informed that on 18 September 2017 Tim Watts, a
director, exercised options over 1,182,813 ordinary shares of 1p
each ("Ordinary Shares") in the Company.
246,072 of these options were granted under the Company's 2007
Long Term Incentive Plan and were exercisable at 1p. 936,741of
these options were granted under the Company's 2015 Deferred Bonus
Plan and were nil cost options.
Following the exercise Mr Watts holds 17,181,767 ordinary shares
of 1p each ("Ordinary Shares") in the Company, 0.55% of the
Company's issued share capital.
The issued share capital of the Company after this exercise is
3,106,253,317 1p ordinary shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Stuart Paynter, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Philippa Gardner/Laura
Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
280 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHKMGMLNLKGNZG
(END) Dow Jones Newswires
September 19, 2017 03:58 ET (07:58 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024